MA30965B1 - Molecules de liaison a lingo et utilisation pharmaceutique de celles-ci - Google Patents
Molecules de liaison a lingo et utilisation pharmaceutique de celles-ciInfo
- Publication number
- MA30965B1 MA30965B1 MA31944A MA31944A MA30965B1 MA 30965 B1 MA30965 B1 MA 30965B1 MA 31944 A MA31944 A MA 31944A MA 31944 A MA31944 A MA 31944A MA 30965 B1 MA30965 B1 MA 30965B1
- Authority
- MA
- Morocco
- Prior art keywords
- binding molecule
- binding molecules
- polynucleotide
- pharmaceutical use
- lingo
- Prior art date
Links
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 241000282693 Cercopithecidae Species 0.000 abstract 1
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 206010012305 Demyelination Diseases 0.000 abstract 1
- 210000003050 axon Anatomy 0.000 abstract 1
- 230000003376 axonal effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE UNE MOLÉCULE DE LIAISON QUI EST CAPABLE DE SE LIER AU POLYPEPTIDE LINGO HUMAIN, DE SINGE CYNOMOLGUS ET DE RAT, UN POLYNUCLÉOTIDE CODANT POUR UNE TELLE MOLÉCULE DE LIAISON ; UN VECTEUR D'EXPRESSION COMPRENANT LEDIT POLYNUCLÉOTIDE ; UN SYSTÈME D'EXPRESSION COMPRENANT UN POLYNUCLÉOTIDE CAPABLE DE PRODUIRE UNE MOLÉCULE DE LIAISON ; UNE CELLULE HÔTE ISOLÉE QUI COMPREND UN SYSTÈME D'EXPRESSION TEL QUE DÉFINI CI-DESSUS ; L'UTILISATION D'UNE TELLE MOLÉCULE DE LIAISON EN TANT QU'UN PRODUIT PHARMACEUTIQUE, NOTAMMENT DANS LE TRAITEMENT DESTINÉ À PROMOUVOIR LA RÉGÉNÉRATION/PLASTICITÉ AXONALE ; UNE COMPOSITION PHARMACEUTIQUE COMPRENANT LADITE MOLÉCULE DE LIAISON ; ET UN PROCÉDÉ DE TRAITEMENT DE MALADIES ASSOCIÉES À LA DÉGÉNÉRESCENCE AXONALE ET À LA DÉMYÉLINISATION.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06124350 | 2006-11-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30965B1 true MA30965B1 (fr) | 2009-12-01 |
Family
ID=38325542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA31944A MA30965B1 (fr) | 2006-11-17 | 2009-06-03 | Molecules de liaison a lingo et utilisation pharmaceutique de celles-ci |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US8299221B2 (fr) |
| EP (2) | EP2084190B1 (fr) |
| JP (2) | JP5647414B2 (fr) |
| KR (1) | KR20090078353A (fr) |
| CN (2) | CN103351437A (fr) |
| AR (1) | AR063829A1 (fr) |
| AT (1) | ATE502960T1 (fr) |
| AU (1) | AU2007321817A1 (fr) |
| BR (1) | BRPI0718406A2 (fr) |
| CA (1) | CA2669181A1 (fr) |
| CL (1) | CL2007003303A1 (fr) |
| CO (1) | CO6180433A2 (fr) |
| CR (1) | CR10756A (fr) |
| DE (1) | DE602007013445D1 (fr) |
| EC (1) | ECSP099332A (fr) |
| ES (1) | ES2363622T3 (fr) |
| GT (1) | GT200900121A (fr) |
| IL (1) | IL198313A0 (fr) |
| MA (1) | MA30965B1 (fr) |
| MX (1) | MX2009005175A (fr) |
| NO (1) | NO20092331L (fr) |
| PE (1) | PE20081392A1 (fr) |
| RU (1) | RU2009122514A (fr) |
| TN (1) | TN2009000190A1 (fr) |
| TW (1) | TW200831534A (fr) |
| WO (1) | WO2008058736A1 (fr) |
| ZA (1) | ZA200902409B (fr) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1606409T3 (pl) | 2003-03-19 | 2011-02-28 | Biogen Ma Inc | Białko wiążące receptor Nogo |
| PL1776136T3 (pl) | 2004-06-24 | 2013-03-29 | Biogen Ma Inc | Leczenie stanów związanych z demielinizacją |
| SG10201508322SA (en) | 2005-07-08 | 2015-11-27 | Biogen Ma Inc | Sp35 antibodies and uses thereof |
| NZ569428A (en) * | 2005-12-02 | 2012-11-30 | Biogen Idec Inc | Treatment of conditions involving demyelination with a Sp35 antagonist |
| EP2068866A4 (fr) | 2006-07-24 | 2010-04-07 | Biogen Idec Inc | Procedes pour favoriser la myelinisation, la survie neuronale et la differenciation des oligodendrocytes par administration d'antagonistes de sp35 ou trka |
| US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| US20100297121A1 (en) * | 2007-10-11 | 2010-11-25 | Biogen Idec Ma Inc. | Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists |
| EP2217697B1 (fr) * | 2007-11-08 | 2015-06-10 | Biogen MA Inc. | Utilisation des antagonistes de lingo-4 dans le traitement d'états mettant en jeu une démyélination |
| WO2010005570A2 (fr) | 2008-07-09 | 2010-01-14 | Biogen Idec Ma Inc. | Compositions comprenant des anticorps anti-lingo ou leurs fragments |
| WO2011139714A2 (fr) | 2010-04-26 | 2011-11-10 | Atyr Pharma, Inc. | Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps se rapportant à des fragments protéiques de la cystéinyl-arnt synthétase |
| CN103096910A (zh) | 2010-04-27 | 2013-05-08 | Atyr医药公司 | 与苏氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| CN103096911B (zh) | 2010-04-27 | 2018-05-29 | Atyr 医药公司 | 与异亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| CN103097524B (zh) | 2010-04-28 | 2016-08-03 | Atyr医药公司 | 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| CN103097523B (zh) | 2010-04-29 | 2016-09-28 | Atyr医药公司 | 与天冬酰胺酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| AU2011248457B2 (en) | 2010-04-29 | 2017-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases |
| WO2011140132A2 (fr) | 2010-05-03 | 2011-11-10 | Atyr Pharma, Inc. | Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées à des fragments protéiques de phénylalanyl-alpha-arnt-synthétases |
| US8946157B2 (en) | 2010-05-03 | 2015-02-03 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases |
| EP2566515B1 (fr) | 2010-05-03 | 2017-08-02 | aTyr Pharma, Inc. | Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps liées à des fragments protéiques d'arginyle-arnt synthétases |
| CA2797978C (fr) | 2010-05-03 | 2019-12-03 | Atyr Pharma, Inc. | Decouverte innovante de compositions therapeutiques, diagnostiques et a base d'anticorps liees des fragments proteiques de methionyl-arnt-synthetases |
| CN102985103A (zh) | 2010-05-04 | 2013-03-20 | Atyr医药公司 | 与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现 |
| JP6008843B2 (ja) | 2010-05-04 | 2016-10-19 | エータイアー ファーマ， インコーポレイテッド | グルタミル−プロリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| US8945541B2 (en) | 2010-05-14 | 2015-02-03 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases |
| WO2011146410A2 (fr) | 2010-05-17 | 2011-11-24 | Atyr Pharma, Inc. | Découverte innovante de compositions thérapeutiques, de diagnostic, et d'anticorps associées à des fragments protéiques de leucyl-arnt synthétases |
| CA2800375C (fr) | 2010-05-27 | 2021-03-09 | Atyr Pharma, Inc. | Decouverte innovante de compositions therapeutiques, de diagnostic et d'anticorps liees a fragments proteiques de glutaminyl-arnt synthetases |
| CN103118694B (zh) | 2010-06-01 | 2016-08-03 | Atyr医药公司 | 与赖氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现 |
| US8999321B2 (en) | 2010-07-12 | 2015-04-07 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
| CA2804416C (fr) | 2010-07-12 | 2020-04-28 | Atyr Pharma, Inc. | Decouverte innovante de compositions therapeutiques, de diagnostic et d'anticorps se rapportant a des fragments proteiques de glycyl-arnt synthetases |
| KR102099730B1 (ko) | 2010-07-12 | 2020-04-16 | 에이티와이알 파마, 인코포레이티드 | 아스파르틸trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견 |
| CA2804424C (fr) | 2010-07-12 | 2021-03-30 | Atyr Pharma, Inc. | Decouverte innovante de compositions therapeutiques, diagnostiques et d'anticorps se rapportant a des fragments proteiques d' histidyle-arnt synthetases |
| CA2808539C (fr) | 2010-08-25 | 2021-05-25 | Atyr Pharma, Inc. | Decouverte innovante de compositions therapeutiques, diagnostiques et d'anticorps associees a des fragments proteiniques des tyrosyl-arnt synthetases |
| CA2812795C (fr) | 2010-10-06 | 2021-08-31 | Atyr Pharma, Inc. | Decouverte innovante de fragments de proteine de tryptophanyle arnt synthetases associes a des compositions therapeutiques, diagnostiques et d'anticorps |
| US9714419B2 (en) | 2011-08-09 | 2017-07-25 | Atyr Pharma, Inc. | PEGylated tyrosyl-tRNA synthetase polypeptides |
| US9822353B2 (en) | 2011-12-06 | 2017-11-21 | Atyr Pharma, Inc. | PEGylated aspartyl-tRNA synthetase polypeptides |
| US9816084B2 (en) | 2011-12-06 | 2017-11-14 | Atyr Pharma, Inc. | Aspartyl-tRNA synthetases |
| CN104220461A (zh) | 2011-12-29 | 2014-12-17 | Atyr医药公司 | 天冬氨酰-tRNA合成酶-FC缀合物 |
| WO2013112859A1 (fr) | 2012-01-27 | 2013-08-01 | New York University | Méthode d'amélioration de la remyélinisation à l'aide d'inhibiteurs gli1 |
| MX381731B (es) | 2012-05-14 | 2025-03-13 | Biogen Ma Inc | Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras. |
| JP6397479B2 (ja) | 2013-03-15 | 2018-09-26 | エータイアー ファーマ， インコーポレイテッド | ヒスチジル−ｔＲＮＡシンテターゼＦｃコンジュゲート |
| HK1246810A1 (zh) | 2015-01-08 | 2018-09-14 | Biogen Ma Inc. | Lingo-1对抗药及用於治疗脱髓鞘疾病的用途 |
| CN113079470B (zh) * | 2015-01-26 | 2025-02-18 | 苹果公司 | 提高水平和垂直定位准确性的设备和方法 |
| KR20190039134A (ko) * | 2016-07-13 | 2019-04-10 | 바이오젠 엠에이 인코포레이티드 | Lingo-1 길항제의 투약 섭생 및 탈수초성 질환의 치료를 위한 용도 |
| CN110536694A (zh) | 2017-04-20 | 2019-12-03 | Atyr 医药公司 | 用于治疗肺部炎症的组合物和方法 |
| KR102414826B1 (ko) | 2020-06-18 | 2022-06-30 | 삼성전기주식회사 | 코일 부품 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308573D0 (en) | 1983-03-29 | 1983-05-05 | British Nuclear Fuels Ltd | Filament impregnating/coating |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP0281604B1 (fr) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Molecules de liaison de chaines de polypeptide simples |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| ATE132187T1 (de) | 1989-02-13 | 1996-01-15 | Schering Ag | Fledermausspeichel-plasminogenaktivator vpa-alpha 1 |
| PL1606409T3 (pl) | 2003-03-19 | 2011-02-28 | Biogen Ma Inc | Białko wiążące receptor Nogo |
| ES2352551T3 (es) * | 2003-03-19 | 2011-02-21 | Biogen Idec Ma Inc. | Proteína de unión a receptor nogo. |
| US20050214288A1 (en) * | 2004-03-26 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies against Nogo receptor |
| PL1776136T3 (pl) * | 2004-06-24 | 2013-03-29 | Biogen Ma Inc | Leczenie stanów związanych z demielinizacją |
| SG10201508322SA (en) | 2005-07-08 | 2015-11-27 | Biogen Ma Inc | Sp35 antibodies and uses thereof |
-
2007
- 2007-11-15 AT AT07846601T patent/ATE502960T1/de not_active IP Right Cessation
- 2007-11-15 CN CN2013102559773A patent/CN103351437A/zh active Pending
- 2007-11-15 ES ES07846601T patent/ES2363622T3/es active Active
- 2007-11-15 MX MX2009005175A patent/MX2009005175A/es not_active Application Discontinuation
- 2007-11-15 WO PCT/EP2007/009880 patent/WO2008058736A1/fr not_active Ceased
- 2007-11-15 RU RU2009122514/10A patent/RU2009122514A/ru not_active Application Discontinuation
- 2007-11-15 CN CN2007800415830A patent/CN101553506B/zh not_active Expired - Fee Related
- 2007-11-15 CA CA002669181A patent/CA2669181A1/fr not_active Abandoned
- 2007-11-15 PE PE2007001587A patent/PE20081392A1/es not_active Application Discontinuation
- 2007-11-15 DE DE602007013445T patent/DE602007013445D1/de active Active
- 2007-11-15 EP EP07846601A patent/EP2084190B1/fr not_active Revoked
- 2007-11-15 US US12/514,542 patent/US8299221B2/en not_active Expired - Fee Related
- 2007-11-15 AU AU2007321817A patent/AU2007321817A1/en not_active Abandoned
- 2007-11-15 KR KR1020097009952A patent/KR20090078353A/ko not_active Ceased
- 2007-11-15 AR ARP070105078A patent/AR063829A1/es not_active Application Discontinuation
- 2007-11-15 BR BRPI0718406-9A patent/BRPI0718406A2/pt not_active IP Right Cessation
- 2007-11-15 JP JP2009536654A patent/JP5647414B2/ja not_active Expired - Fee Related
- 2007-11-15 EP EP11151300A patent/EP2395022A1/fr not_active Withdrawn
- 2007-11-16 TW TW096143597A patent/TW200831534A/zh unknown
- 2007-11-16 CL CL200703303A patent/CL2007003303A1/es unknown
-
2009
- 2009-04-07 ZA ZA200902409A patent/ZA200902409B/xx unknown
- 2009-04-23 IL IL198313A patent/IL198313A0/en unknown
- 2009-04-29 CR CR10756A patent/CR10756A/es not_active Application Discontinuation
- 2009-05-12 GT GT200900121A patent/GT200900121A/es unknown
- 2009-05-12 CO CO09048055A patent/CO6180433A2/es not_active Application Discontinuation
- 2009-05-15 EC EC2009009332A patent/ECSP099332A/es unknown
- 2009-05-15 TN TNP2009000190A patent/TN2009000190A1/fr unknown
- 2009-06-03 MA MA31944A patent/MA30965B1/fr unknown
- 2009-06-17 NO NO20092331A patent/NO20092331L/no not_active Application Discontinuation
-
2012
- 2012-09-14 US US13/616,226 patent/US20130071400A1/en not_active Abandoned
- 2012-10-04 JP JP2012222370A patent/JP2013056888A/ja active Pending
-
2013
- 2013-09-26 US US14/037,841 patent/US20140037639A1/en not_active Abandoned
-
2014
- 2014-05-19 US US14/280,933 patent/US20140255415A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA30965B1 (fr) | Molecules de liaison a lingo et utilisation pharmaceutique de celles-ci | |
| Fabre et al. | Label-free quantitative proteomics reveals the dynamics of proteasome complexes composition and stoichiometry in a wide range of human cell lines | |
| Kumagai et al. | ADP-ribosylation of rho p21 inhibits lysophosphatidic acid-induced protein tyrosine phosphorylation and phosphatidylinositol 3-kinase activation in cultured Swiss 3T3 cells. | |
| Cai et al. | Biodegradation of composite resin with ester linkages: Identifying human salivary enzyme activity with a potential role in the esterolytic process | |
| Heuer et al. | Mapping Features of HIV-1 Integrase Near Selected Sites on Viral and Target DNA Molecules in an Active Enzyme− DNA Complex by Photo-Cross-Linking | |
| Ishibashi et al. | Acetylation of vertebrate H2A. Z and its effect on the structure of the nucleosome | |
| Tarsio et al. | Decreased interaction of fibronectin, type iv collagen, and heparin due to nonenzymic glycation. Implications for diabetes mellitus | |
| RU2009135802A (ru) | Способ активации хелперных т-клеток и композиция для применения в данном способе | |
| ATE527279T1 (de) | Zusammensetzungen und verfahren zur modulation des immunsystems | |
| EP4249064A3 (fr) | Nouvelle protéine de fusion spécifique à cd137 et pd-l1 | |
| Macmillan et al. | Solid-phase synthesis of thioether-linked glycopeptide mimics for application to glycoprotein semisynthesis | |
| Rabalski et al. | Evaluation of chemically-cleavable linkers for quantitative mapping of small molecule-cysteinome reactivity | |
| Valente et al. | Acquired enamel pellicle engineered peptides: effects on hydroxyapatite crystal growth | |
| Md Fadilah et al. | Discovery of bioactive peptides as therapeutic agents for skin wound repair | |
| Trautmann et al. | Is the proteomic composition of the salivary pellicle dependent on the substrate material? | |
| Maret et al. | The ATP/metallothionein interaction: NMR and STM | |
| Gavish et al. | Human α2-macroglobulin is an osteogenic growth peptide-binding protein | |
| Zheng et al. | A new method for synthesis of peptide thioesters via irreversible N-to-S acyl transfer | |
| EP1597271B1 (fr) | Peptides diriges contre des autoanticorps resultant de l'intolerance au froid, et leur utilisation | |
| Fish et al. | Shear-Stress Initiates Signal Two of NLRP3 Inflammasome Activation in LPS-Primed Macrophages through Piezo1 | |
| Bao et al. | Inhibition of dipeptidyl-peptidase 4 induces upregulation of the late cornified envelope cluster in keratinocytes | |
| Sivagurunathan et al. | Thrombin inhibits osteoclast differentiation through a non-proteolytic mechanism | |
| Pinto et al. | Novel perspectives on the pathogenesis of Lonomia obliqua caterpillar envenomation based on assessment of host response by gene expression analysis | |
| NO20061678L (no) | NOGO-A bindingsmolekyler og funmsoytiske anvendelser derav | |
| Bennmann et al. | Glycation of the high affinity NGF-receptor and RAGE leads to reduced ligand affinity |